Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Recurrent Small Lymphocytic Lymphoma Clinical Trial

Official title:

A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02005289
• Other study ID #: OSU-13031
• Secondary ID: NCI-2013-02082
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 17, 2014
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well anti-cluster of differentiation (CD)19 monoclonal antibody MOR00208 and lenalidomide work in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia, small lymphocytic lymphoma, or prolymphocytic leukemia. Monoclonal antibodies, such as anti-CD19 monoclonal antibody MOR00208, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving anti-CD19 monoclonal antibody MOR00208 and lenalidomide may kill more cancer cells.

Description:

PRIMARY OBJECTIVES:

I. To determine the overall response rate (ORR) at 6 months for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)/prolymphocytic leukemia (PLL) treated with the combination of MOR00208 plus lenalidomide.

II. To determine the overall response rate (ORR) at 6 months for patients with treatment-naive CLL/SLL/PLL treated with the combination of MOR00208 plus lenalidomide.

III.To obtain preliminary data on toxicity profiles and efficacy with the combination of MOR00208 plus lenalidomide in patients with Richter's Transformation IV. To obtain preliminary data on efficacy of MOR00208 in patients with progressive disease on ibrutinib monotherapy

SECONDARY OBJECTIVES:

I. To determine the overall response rate (ORR) at 12 months for patients with untreated CLL/SLL/PLL or relapsed/refractory disease treated with the combination of MOR00208 plus lenalidomide.

II. To determine the complete response (CR) rate, nodular partial response (nPR) rate, partial response (PR) rate, and stable disease (SD) rate for patients with untreated CLL/SLL/PLL or relapsed or refractory disease treated with the combination of MOR00208 plus lenalidomide.

III. To summarize the progression free survival (PFS), time to next treatment, and overall survival (OS) for each of two cohorts of patients treated with this regimen.

IV. To evaluate toxicity with this regimen, including frequency and severity of toxicities, dose reduction requirements, and adverse events requiring drug discontinuation.

V. To perform baseline analysis of patients enrolled on this trial including fluorescence in situ hybridization (FISH), stimulated karyotype, zeta-chain-associated protein kinase 70 (Zap-70) methylation, and immunoglobulin variable region heavy chain (IgVH) mutational status and describe relationships between these biomarkers and ORR or PFS for each of two cohorts with this regimen.

VI. To determine the effect of this regimen on total immunoglobulins, CD4+ and CD8+ T cells, natural killer (NK) cells, and interleukin-21 receptor (IL-21R) expression on CLL cells.

VII. To determine whether NK cells and T cells are activated in response to MOR00208 alone or in combination with lenalidomide.

VIII. To estimate the rate of minimal residual disease (MRD) in patients achieving CR, and whether this correlates with PFS.

OUTLINE:

Patients receive anti-CD19 monoclonal antibody MOR00208 intravenously (IV) over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1) and lenalidomide orally (PO) daily on days 1-28 (days 9-28 of course 1). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 41
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of intermediate or high risk CLL, SLL, or B cell (B)-PLL by Biennial International Workshop on CLL (IWCLL) 2008 criteria who have

• COHORT 1: previously untreated disease AND refuse or are ineligible for approved chemo- and/or -immunotherapy options for untreated CLL/SLL/PLL

• COHORT 2: previously received at least one therapy for their disease

• All patients must satisfy one of the following criteria for active disease requiring therapy:

• Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or thrombocytopenia)

• Massive (>= 6 cm below the costal margin), progressive or symptomatic splenomegaly

• Massive nodes (>= 10 cm) or progressive or symptomatic lymphadenopathy

• Constitutional symptoms, which include any of the following:

• Unintentional weight loss of 10% or more within 6 months

• Significant fatigue limiting activity

• Fevers >= 100.5 degrees Fahrenheit (F) for 2 weeks or more without evidence of infection

• Night sweats > 1 month without evidence of infection

• Patients with a history of Richter's transformation are eligible if they now have evidence of CLL only, with < 10% large cells in the bone marrow

• Creatinine =< 2

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal

• Bilirubin =< 2 times the upper limit of normal, unless related to disease or Gilbert's disease

• Platelets >= 30 x 10^9/L and absence of active bleeding

• Absolute neutrophil count (ANC) >= 1000/mm^3 unless due to CLL involvement of the marrow

• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2

• Patients must not have secondary cancers that result in a life expectancy of < 2 years or that would confound assessment of toxicity in this study

• Patients must provide written informed consent; a signed copy of the consent form will be retained in the patient's chart

• Patients must be able to receive outpatient treatment and follow-up at the treating institution

• Patients must have completed all CLL therapies > 4 weeks prior to first study dose; palliative steroids are allowed, but must be at a dose equivalent of =< 20 mg prednisone daily for at least 1 week prior to treatment initiation

• Patients capable of reproduction and male patients who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the study and for 2 months following the completion of their last treatment; females of childbearing potential must have a negative beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 3 days of first study dose; female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have the ß-hCG pregnancy test waived

• Patients must be able to swallow whole capsules

• Inclusion of women and minorities: patients of both genders and all racial/ethnic groups are eligible for the study if they meet eligibility criteria outlined; to date, there is no information that suggests that differences in drug metabolism or disease response would be expected in one group compared to another; the small number of patients in a phase II trial precludes any analysis of data to compare patient subgroups based on gender or race/ethnicity

Exclusion Criteria:

• Previous treatment with a CD19 antibody; prior lenalidomide is acceptable for patients on cohort 2

• Patients who have received alemtuzumab within the previous 6 months

• Patients with active Richter's transformation

• Patients with active graft versus host disease or active autoimmune condition related to CLL

• Female subject that is pregnant or breastfeeding; women of childbearing potential and men must agree to use adequate contraception prior to study entry, duration of study participation, and 30 days following study completion; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women

• Patients with congestive heart failure in whom pre-treatment hydration would be prohibitive; New York Heart Association (NYHA) class III/IV congestive heart failure (CHF) is excluded

• Patients who have had treatment for CLL within 4 weeks, although palliative steroids are acceptable at doses =< 20 mg prednisone daily

• Failure to recover from toxicity of previous radiotherapy or chemotherapy to grade 1

• Patients with active infections requiring IV antibiotic/antiviral therapy are not eligible for entry onto the study until resolution of the infection; patients on prophylactic antibiotics or antivirals are acceptable

• Patients with a known hypersensitivity to lenalidomide

• Patients who are known to be human immunodeficiency virus (HIV) or hepatitis C positive

• Patients who are known to have hepatitis B infection or who are hepatitis B core antibody or surface antigen positive; patients receiving prophylactic intravenous immunoglobulin (IVIG) may have false positive hepatitis serologies; patients who are on IVIG who have positive hepatitis serologies must have a negative hepatitis B deoxyribonucleic acid (DNA) to be eligible

• Patients with a history of prior malignancy other than CLL that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity, or limit survival to 2 years; patients with basal or squamous skin carcinoma, cervical carcinoma in situ on biopsy, localized breast cancer requiring hormonal therapy or localized prostate cancer (Gleason score < 5) are eligible

• Patients with substance abuse or other medical or psychiatric conditions that, in the opinion of the investigator, would confound study interpretation or affect the patient's ability to tolerate or complete the study

Related Conditions & MeSH terms

• Contiguous Stage II Small Lymphocytic Lymphoma
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Leukemia, Prolymphocytic
• Lymphoma
• Noncontiguous Stage II Small Lymphocytic Lymphoma
• Prolymphocytic Leukemia
• Recurrent Small Lymphocytic Lymphoma
• Refractory Chronic Lymphocytic Leukemia
• Stage I Chronic Lymphocytic Leukemia
• Stage I Small Lymphocytic Lymphoma
• Stage II Chronic Lymphocytic Leukemia
• Stage III Chronic Lymphocytic Leukemia
• Stage III Small Lymphocytic Lymphoma
• Stage IV Chronic Lymphocytic Leukemia
• Stage IV Small Lymphocytic Lymphoma

Intervention

Biological:
• MOR00208
Given by IV infusion

Drug:
• lenalidomide
Given PO

Other:
• Correlative Studies
Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.

Locations

Country	Name	City	State
United States	The Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center	MorphoSys AG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients who achieve a response (i.e. CR, complete response with incomplete recovery [CRi], nPR, or PR), as defined according to the IWCLL 2008 criteria	Within each cohort, the proportion of patients who achieve an overall response will be estimated by the sum of the number of complete responses, complete responses with incomplete recovery, nodular partial responses, and partial responses divided by the total number of evaluable patients. Ninety percent exact binomial confidence intervals for the true overall response rate will be calculated for those patients included to evaluate the decision criteria.	up to 6 months
Secondary	ORR	The ORR with 90% exact binomial confidence intervals will be calculated. The degree of response for evaluable patients will also be summarized. In addition, the number of patients who achieve CR but remain positive for MRD will be documented.	At 12 months
Secondary	PFS	PFS will be summarized with simple descriptive statistics obtained using the Kaplan-Meier method.	From the date of registration to date of relapse or death, assessed up to 12 months
Secondary	Time to next treatment	Time to next treatment will be summarized with simple descriptive statistics obtained using the Kaplan-Meier method.	From date of registration until date of next treatment or death, censoring those alive who have not started another treatment at last follow-up, assessed up to 12 months
Secondary	OS	OS will be summarized with simple descriptive statistics obtained using the Kaplan-Meier method.	From date of registration until date of death or last follow-up, assessed up to 12 months
Secondary	Results of FISH	Relationships between FISH variables and ORR or PFS will be explored graphically (e.g. side-by-side boxplots or Kaplan-Meier plots), where estimates with confidence intervals will be presented as the primary method of analysis due to the limited number of patients.	Baseline
Secondary	Results of stimulated karyotype	Relationships between stimulated karyotype variables and ORR or PFS will be explored graphically (e.g. side-by-side boxplots or Kaplan-Meier plots), where estimates with confidence intervals will be presented as the primary method of analysis due to the limited number of patients.	Baseline
Secondary	Zap-70 methylation	Relationships between Zap-70 variables and ORR or PFS will be explored graphically (e.g. side-by-side boxplots or Kaplan-Meier plots), where estimates with confidence intervals will be presented as the primary method of analysis due to the limited number of patients.	Baseline
Secondary	IgVH mutational status	Relationships between IgVH variables and ORR or PFS will be explored graphically (e.g. side-by-side boxplots or Kaplan-Meier plots), where estimates with confidence intervals will be presented as the primary method of analysis due to the limited number of patients.	Baseline
Secondary	Effects of combined therapy with MOR00208 and lenalidomide on CD4+ T cells using flow cytometry during the course of protocol therapy	Patterns will be explored graphically using box plots and/or individual time plots as well as analytically with either repeated measures analysis of variance or Friedman's nonparametric test, recognizing the inherent limitations due to sample size.	Up to 12 months
Secondary	Effects of combined therapy with MOR00208 and lenalidomide on CD8+ T cells during the course of protocol therapy by flow cytometry	Patterns will be explored graphically using box plots and/or individual time plots as well as analytically with either repeated measures analysis of variance or Friedman's nonparametric test, recognizing the inherent limitations due to sample size.	Up to 12 months
Secondary	Effects of combined therapy with MOR00208 and lenalidomide on NK cells during the course of protocol therapy by flow cytometry	Patterns will be explored graphically using box plots and/or individual time plots as well as analytically with either repeated measures analysis of variance or Friedman's nonparametric test, recognizing the inherent limitations due to sample size.	Up to 12 months
Secondary	Changes in IL-21R expression		Baseline to up to 12 months
Secondary	Changes in expression of select genes associated with B-cell activation		Baseline up to 12 months
Secondary	Incidence of adverse events as graded per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed for each cohort to determine toxicity patterns. The incidence of severe (grade 3+) adverse events or toxicities will be described.	Up to 12 months
Secondary	Tolerability assessed by the number of patients who require dose modifications and/or dose delays		Up to 12 months

External Links

•   The Jamesline